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Introduction
============

Hemophagocytic lymphohistiocytosis (HLH) involves the inappropriate stimulation of macrophage cells with hemophagocytosis \[[@REF1]\]. Generally, it occurs in children with primary immunodeficiency. In adults, HLH often appears as a result of infectious disease, autoimmune disease, or malignancy. HLH is an increasingly recognized disorder in adults \[[@REF2]\]. The diagnosis of acquired HLH in adults is often difficult with a broad differential diagnosis. Furthermore, therapeutic decision-making continues to be on the basis of clinical experience and expert opinion \[[@REF2]\].

In Sub-Saharan Africa, there have been very few studies on HLH in adult patients \[[@REF3]-[@REF5]\]. The observations from these studies show some clinical and biological atypia that could indicate the specificity of HLH for black African people. Therefore, this study focuses on clinical, biological, and cytological presentations, etiological profile, and outcome factors related to HLH in the black African adult population.

Materials and methods
=====================

A retrospective multicentre study was carried out in three medical units in Senegal: Department of Internal Medicine at Pikine Teaching Hospital, and Department of Internal Medicine and Department of Nephrology at Aristide Le Dantec Teaching Hospital; the study covered the period from January 1, 2012 to March 30, 2015. The data was obtained through medical records.

This study included all patients aged 18 and older who were hospitalized during the study period with a Hemophagocytosis Score (HScore) of ≥202 (with probabilities of acquired HLH of \>90%) (Figure [1](#FIG1){ref-type="fig"}) \[[@REF6]\]. Patients with lost or incomplete medical records (n = 3) were not included in this study.
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For each included patient, the epidemiological, clinical, biological, cytohistological, therapeutic, and evolutionary data were noted in a record chart. Criteria for the diagnosis of systemic diseases were based on Systemic Lupus International Collaborating Clinics criteria, American College of Rheumatology/European League Against Rheumatism 2013 classification criteria, and American-European 2002 Consensus Group criteria for lupus, systemic scleroderma, and Primary Sjogren\'s syndrome, respectively \[[@REF7]-[@REF9]\]. We used IBM SPSS Statistics for Windows, Version 20.0 (IBM Corp., Armonk, NY) for statistical analyses. Continuous variables were presented as means and standard deviation. Categoric variables were presented as proportions. For the analytical study, cases classified as "died" were compared with those classified as "survival" (all patients who were alive until the date of the last evaluation in April 2016 were included) using the Fisher exact test for categoric variables. A p-value of \<0.05 was considered statistically significant.

Results
=======

Series description

Overall, 26 medical records were collected (18 men and eight women), with a male-to-female sex ratio of 2.25:1. The mean age of patients was 41 ±20.2 years old. Patients younger than 40 years old represented 61.5% of the study population.

Clinical and biological data

The different clinical signs recorded in patients included in our series are represented in Table [1](#TAB1){ref-type="table"}. All patients experienced fever, which was hectic in approximately 75% of cases. Nine cases of central neurological signs were noted with a normal cytochemical and bacteriological exploration of the cerebrospinal fluid (CSF). Cerebral MRI performed on one of those patients was normal. Regarding the blood count, cytopenia was constant. Anemia was noted in all patients with an average hemoglobin level of 6.1 g/dL. Autoimmune hemolytic anemia was noted in six patients. Thrombopenia was present in 17 patients and was associated with a hemorrhagic syndrome in five patients. Thrombocytosis was recorded in three patients. The other biological abnormalities recorded in our patients are mentioned in Table [2](#TAB2){ref-type="table"}.

###### Main clinical signs of HLH recorded in our series

HLH: hemophagocytic lymphohistiocytosis

  ------------------------------------------------------------- -----------
  Clinical signs                                                N (%)
  Fever                                                         26 (100)
  Adenopathies                                                  18 (69.2)
  Hepatomegaly                                                  14 (53.8)
  Splenomegaly                                                  9 (34.6)
  Serositis                                                     10 (38.4)
  Neurological signs (conscious disorders, convulsions)         9 (34.5)
  Pulmonary signs (dyspnea, cough, respiratory insufficiency)   4 (15.3)
  ------------------------------------------------------------- -----------

###### Main biological signs of HLH recorded in our series

HLH: hemophagocytic lymphohistiocytosis; CRP: c-reactive protein; SR: sedimentation rate at the first hour; LDH: lactic acid dehydrogenase; N: number of patients in whom biological investigations were performed; n: number of patients in whom biological abnormalities were noted

  --------------------------- ----------- -----------
  Biological manifestations   N (%)       n/N (%)
  High CRP                    26 (100)    25 (96.2)
  Elevated SR                 21 (80.7)   19 (90.4)
  Hyperferritinemia           23 (88.4)   23 (100)
  Hypofibrinemia              19 (73)     3 (15.7)
  Hemostasis disorders        22 (84.6)   7 (31.8)
  Hepatic cytolysis           23 (88.4)   13 (56.5)
  Hepatic cholestasis         15 (57.6)   13 (86.3)
  Hypertriglyceridemia        20 (77)     16 (80)
  Hyponatremia                22 (84.6)   18 (81.8)
  Renal function disorders    26 (100)    8 (30.7)
  High LDH                    21 (80.7)   17 (90)
  --------------------------- ----------- -----------

The increases in triglyceride levels, lactic acid dehydrogenase levels, and hepatic enzymes were moderate. Renal impairment markers (e.g., proteinuria, hematuria, aseptic leukocyturia) were recorded in all cases. Acute renal failure was noted in eight patients. Glomerular nephropathy was found and featured an impure nephrotic syndrome or rapidly progressive glomerulonephritis (RPGN) in four patients in our study. The renal histology of one of these patients found a collapsing focal segmental glomerulosclerosis (Figure [2](#FIG2){ref-type="fig"}).
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Cytological and etiological data

The myelogram revealed a hemophagocytosis in 76% of cases (Figure [3](#FIG3){ref-type="fig"}) and showed dysmyelopoiesis in 12 patients. The dysmyelopoiesis essentially involved the erythrocyte line with abnormalities such as karyorrhexis (Figure [4](#FIG4){ref-type="fig"}), nucleo-cytoplasmic maturation asynchronism, dyskaryosis, binucleated erythroblasts, and basophilic punctuations. The presence of degranulated cells and giant cells was noted. A medullar plasmacytosis was also found in eight patients, outside of a myeloma context.

![Macrophage activation\
Cytology of the medullar fluid showing an activated macrophage (green arrow) engulfing a hematopoietic cell (erythrocyte)](cureus-0012-00000007258-i03){#FIG3}

![Dysmyelopoiesis\
Medullar cytology of a patient showing a dysmyelopoiesis type of karyorrhexis (green arrow)](cureus-0012-00000007258-i04){#FIG4}

For the field study, the HLH triggering factor and lymph node biopsy were helpful in eight cases, and the myelogram in two cases. The conditions and/or factors of the patients are noted in Table [3](#TAB3){ref-type="table"}. In two patients, the cause of HLH was not identified.

###### Main fields and/or triggering factors of adult HLH found in our series

HLH: hemophagocytic lymphohistiocytosis

  ---------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------
  Etiological framework                                                  Main etiologies
  Hematologic malignancies (11 patients, 42.3%)                          Hodgkin\'s disease (four cases)
  Diffuse large cell B lymphoma (three cases)                            
  T-cell lymphoma                                                        
  Burkitt's lymphoma                                                     
  Acute myeloid leukemia                                                 
  Multiple myeloma                                                       
  Infections (12 patients, 46.1%)                                        Bacteria: tuberculosis (three cases), atypical mycobacteriosis, pyomyositis, sepsis by Enterobacter and Burkholderia cepacia
  Virus: Epstein-Barr virus, hepatitis B, human immunodeficiency virus   
  Parasite: malaria                                                      
  Mycosis: systemic aspergillosis                                        
  Systemic diseases (six patients, 23%)                                  Lupus (two cases)
  Scleroderma                                                            
  Primitive Sjogren\'s                                                   
  Microscopic polyangiitis                                               
  Multicentric Castleman disease                                         
  Primary immunodeficiency (one patient, 3.8%)                           Common variable immunodeficiency
  Unfound etiology (two patients, 7.6%)                                   
  ---------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------

Therapeutic and evolutionary data

The specific treatment of HLH is found in corticotherapy (bolus of methylprednisolone for three days, followed by oral prednisone). Etoposide (VP-16) was administrated to seven patients. It was associated with corticotherapy in four cases. Specific treatment of the causal pathology (chemotherapy, anti-infectious treatment, immunosuppressors) was introduced in 65.5% of cases. However, three patients were not under specific treatment.

The mortality rate for HLH was 73.1%. Deaths occurred during hospitalization in 52% of the cases, and nine patients died after a remission period of approximately 5.8 months. The mean survival rate was 45 days. One case of HLH relapse was noted.

Analytical study

The study of the influencing outcome factors of HLH in our series is reported in Table [4](#TAB4){ref-type="table"}. We noted that the male gender and the absence of etiological treatment more frequently correlated with mortality. On the other hand, the age of under 40 years and the absence of both hyperfibrinemia and underlying systemic disease were significantly correlated with patient survival. Furthermore, all patients with agranulocytosis (p: 0.221) or those without corticotherapy (p: 0.09) had higher mortality.

###### Influencing outcome factors of HLH in our series

HLH: hemophagocytic lymphohistiocytosis; OR: observed risk; CI: confidence interval

  ------------------------------- ------------------------ ------------------------ --------- --------------------
  Factors                         Patients died (n = 19)   Patients alive (n = 7)   P-value   OR (95% CI)
  Age of \<40 years               8                        6                        0.04      0.12 (0.01-1.21)
  Male gender                     17                       1                        0.000     51 (3.8-669.4)
  Hemorrhagic syndrome            2                        4                        0.012     0.088 (0.011-0.71)
  Normal or low fibrinemia        2                        3                        0.04      0.11 (0.011-1.14)
  Renal function disorder         7                        1                        0.26      \-
  Myelodysplasia                  9                        3                        0.78      \-
  Hematologic neoplasms           9                        1                        0.07      \-
  Systemic disease                1                        4                        0.003     0.04 (0.003-0.51)
  Infections                      4                        2                        0.68      \-
  Corticotherapy                  13                       7                        0.09      \-
  Etoposide                       5                        2                        0.90      \-
  Etiological treatment absence   11                       1                        0.04      8.2 (0.8-82.6)
  ------------------------------- ------------------------ ------------------------ --------- --------------------

Discussion
==========

HLH in adults is an uncommon condition recently labeled as a pathological entity \[[@REF2]\]. In Sub-Saharan Africa, this pathology has been the subject of only a few case reports \[[@REF3]-[@REF5]\]. We conducted a three-year retrospective and cross-sectional study to collect 26 observations of adult HLH, undertaking the largest African patient series. In this study, we found that HLH generally affects adult male patients.

A variety of conditions including infection, malignancy, autoimmune disorders, and immunosuppression is associated with HLH in adults \[[@REF10]\]. HLH occurred mainly in the presence of underlying hematological malignancies in our patients \[[@REF2],[@REF11]\]. However, the association of acquired HLH with Hodgkin\'s disease, the main hematological malignancies found in our series, was rare \[[@REF12]\]. HLH/autoimmune disease was diagnosed in five of our patients, with two cases of lupus. Regarding these predisposition fields, HLH in adults was mostly triggered by infection \[[@REF13]\]. In our series, a documented infection was recorded in approximately half of the cases. They occurred individually or in a predisposition field: hematological malignancies and primary immunodeficiency.

HLH has a life-threatening clinical presentation that affects a wide range of organ systems \[[@REF2]\]. An important presence of central neurological disorders was noted in this study. Typically, those neurological signs are more described in HLH in children \[[@REF10]\]. However, it is difficult to determine the difference between signs related to HLH and those from the causal pathology. Nevertheless, the clinical assessment findings, as well as the cellularity of CSF, were normal for all those patients. The proportion of renal impairment in our series was high. Some cases of HLH were gathered in a nephrology unit, which could be a source of selection bias. The most specific histological sign noted in our study was collapsing focal segmental glomerulosclerosis. This abnormality was mainly reported in black African patients during acquired HLH \[[@REF14],[@REF15]\].

Cytopenia was the main biological marker of HLH. Anemia, on the other hand, was profound and permanent in most cases. Thrombocytopenia was the most frequent precocious cytopenia of adult HLH \[[@REF1],[@REF2]\]. However, this thrombocytopenia was recorded in only 65% of our patients. Paradoxical thrombocytosis was noted in three of our patients, with two cases of HLH/Hodgkin\'s disease and one with underlying lymphoma T. The association between HLH and thrombocytosis was rarely reported in the literature \[[@REF3]\]. Thrombocytosis occurrence during HLH could be linked to a preexisting chronic inflammation or with underlying hematological malignancies such as Hodgkin\'s disease, in which the association with a thrombocytosis was reported \[[@REF16]\]. Of the medullar hemophagocytosis, the myelogram highlighted dysmyelopoiesis in approximately half of our patients, which could be a cause or consequence of HLH. In fact, exceptional cases of myelodysplastic syndrome (MDS) complicated by HLH were reported \[[@REF17]\]. Additionally, some cytological abnormalities mimicking MDS were described during HLH. They might be related to a cytokine rush that led to cellular damages resulting in morphological changes \[[@REF18]\]. Although cytogenetic examinations were not performed in our patients, the hypothesis of an underlying MDS is unlikely with a mean age of 34 years and the disappearance of peripheral cytopenias with 42% having controlled HLH. The dysmyelopoiesis was recorded regardless of the context of vitamin B12 and/or folic acid deficiency. The dysmyelopoiesis, then, could be one more cytological argument for adult HLH diagnosis in our context.

HLH was also remarkable for the high mortality level in this study. This can be due to the diagnostic delay as well as the presence of underlying hematological malignancies. This analytical study helped identify some prognosis-associated factors of adult HLH. HLH in female patients aged younger than 40 years or with an underlying systemic disease was significantly associated with a good outcome. The absence of etiological treatment was the main poor outcome factor. On the other hand, the use of etoposide was not significantly associated with survival in our patients. Yet, it is presently the first-line treatment of adult HLH \[[@REF11],[@REF19]\]. However, the efficacy of etoposide is dependent on the underlying etiology of HLH \[[@REF11]\].

Conclusions
===========

We conducted the largest case series in a Sub-Saharan African population. Our study consisted of 26 observations, and our analysis revealed the particularities of adult HLH presentation in our population. The significant presence of neurological signs, myelodysplasia, and paradoxical thrombocytosis were important features of adult HLH in our study population. These features should be considered for the diagnostic assessment and management of HLH patients in tropical areas.
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